Sandra Gawchik is a Rheumatology/Immunology physician. OpenAlex indexes 38 publications with 1,148 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Presidents Drive
Presidents House Ccmc
Upland, PA 19013
Telephone
610-876-1249Registry record last updated 8 Jul 2007.
Clinical trials
- T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
Sponsor: MDVI, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202551 payments$21,489openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202513 payments
- Novartis Pharmaceuticals CorporationProgram year202519 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
67.2%Corticosteroid33.4%Fluticasone Propionate27%Symbicort11%Breo Ellipta11%Arnuity Ellipta10%Budesonide-Formoterol Fumarate10%Qvar Redihaler10%Breztri Aerosphere9%Trelegy Ellipta5%Dulera4%Xhance3%Part D<11 patientsLeukotriene Receptor Antagonist14.5%Montelukast Sodium91%Zafirlukast9%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
9.4%Proton pump inhibitor5.3%Omeprazole100%Part D≥16 patientsCorticosteroid4.1%Prednisone100%Part D≥40 patientsAnti-infectives
9.1%Penicillins with extended spectrum4.3%Amoxicillin65%Amoxicillin-Clavulanate Potass35%Part D≥25 patientsMacrolide Antimicrobial3%Azithromycin100%Part D≥24 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial
Allergy and Asthma Proceedings
2018 - Efficacy of MP-Azeflu in the Treatment of Postnasal Drip and Rhinorrhea in Patients with Seasonal Allergic Rhinitis (SAR)
Journal of Allergy and Clinical Immunology
2016 - P324 Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of child symptom assessment
Annals of Allergy Asthma & Immunology
2016 - P325 Time to a clinically-meaningful response with mp-azeflu in children with seasonal allergic rhinitis (SAR)
Annals of Allergy Asthma & Immunology
2016 - Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites
Annals of Allergy Asthma & Immunology
2015
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”